ReviewFrontiers in pharmacology2021
Drug-Induced Idiosyncratic Agranulocytosis - Infrequent but Dangerous.
Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Efficacy and safety of deferiprone for thalassemia: a systematic review and meta-analysis of randomized controlled trials.Systematic reviews · 2025Pooled it
- Hematological parameters in patients with chronic pain on long-term dipyrone therapy followed in a tertiary hospital: a retrospective cohort study.Clinics (Sao Paulo, Brazil) · 2026Article
- Agranulocytosis associated with metamizole among EudraVigilance reports involving methotrexate for rheumatoid arthritis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Pharmacogenomic screening strategy and indicative screening efficiency for antithyroid drug-induced agranulocytosis in the Southern Han Chinese.European journal of clinical pharmacology · 2026Article
- Article
- Factors Influencing the Use of G-CSF in Drug-Induced Agranulocytosis.Hematology reports · 2026Review
- Hematologic follow-up of metamizole-associated Heinz body anemia in dogs.Frontiers in veterinary science · 2026Article
- Ceftazidime-Induced Agranulocytosis: A Case Report.Clinical case reports · 2025Article
- A case of idiosyncratic drug-induced agranulocytosis because of sulbactam/ampicillin.Journal of general and family medicine · 2025Article
- Anastrozole-induced interstitial lung disease followed by tamoxifen-induced agranulocytosis in a patient with breast cancer.International cancer conference journal · 2025Article
- Methotrexate - Safe Backbone for the Treatment of Rheumatoid Arthritis.Current rheumatology reviews · 2025Review
- Drug-induced agranulocytosis: a disproportionality analysis and umbrella review.Frontiers in pharmacology · 2025Article
- Impact of lymphocyte transformation test on the diagnostic accuracy of the culprit drug in drug-induced cytopenias: a case-control study.Frontiers in pharmacology · 2025Article
- Non-chemotherapy drugs inducing agranulocytosis: a disproportionality analysis based on the FAERS database.Frontiers in pharmacology · 2025Article
- Agranulocytosis and Aseptic Meningitis Induced by Sulfamethoxazole-Trimethoprim.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2024Article
- Rates of severe neutropenia and infection risk in patients treated with deferiprone: 28 years of data.Blood advances · 2024Article
- Risk of agranulocytosis with metamizole in comparison with alternative medications based on health records in Spain.European journal of clinical pharmacology · 2024Article
- Predicting non-chemotherapy drug-induced agranulocytosis toxicity through ensemble machine learning approaches.Frontiers in pharmacology · 2024Article
- Significant neutropenia induced by metamizole dependent neutrophil antibodies.Blood transfusion = Trasfusione del sangue · 2024Article
- Pulmonary-Renal Syndrome from Levamisole-Adulterated Cocaine-Induced Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-induced agranulocytosis is a life-threatening side effect that usually manifests as a severe form of neutropenia associated with fever or signs of sepsis. It can occur as a problem in the context of therapy with a wide variety of drug classes. Numerous drugs are capable of triggering the rare idiosyncratic form of agranulocytosis, which, unlike agranulocytosis induced by cytotoxic drugs in cancer chemotherapy, is characterised by "bizzare" type B or hypersensitivity reactions, poor predictability and a mainly low incidence. The idiosyncratic reactions are thought to be initiated by chemically reactive drugs or reactive metabolites that react with proteins and may subsequently elicit an immune response, particularly directed against neutrophils and their precursors. Cells or organs that exhibit specific metabolic and biotransformation activity are therefore frequently affected. In this review, we provide an update on the understanding of drug-induced idiosyncratic agranulocytosis. Using important triggering drugs as examples, we will summarise and discuss the chemical, the biotransformation-related, the mechanistic and the therapeutic basis of this clinically relevant and undesirable side effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.